Managing the Spectrum of Premenstrual Symptoms: A Clinician's Guide
Based on the proceedings of a satellite symposium meeting May 10, 2005, in San Francisco, California
CME Release Date: October 2005
CME Expiration Date for Credit: October 31, 2007
CME Credit: 1
Epidemiology and Etiology of Premenstrual Disorders
Daniel R. Mishell, Jr., MD
The Lyle G. McNeile Professor
Department of Obstetrics and Gynecology
Keck School of Medicine
University of Southern California
Women and Children's Hospital
Los Angeles, California
Contraceptive Redesign: Eliminating Cyclic Symptomatology
Patricia J. Sulak, MD
Professor, Texas A&M College of Medicine
Director, Division of Ambulatory Care
Director, Sex Education Program
Department of Obstetrics and Gynecology
Scott and White Clinic/Memorial Hospital
Temple, Texas
New Approaches to Treating Premenstrual Disorders
Andrea J. Rapkin, MD
Professor
Department of Obstetrics and Gynecology
David Geffen School of Medicine
University of California Los Angeles
Los Angeles, California
ACCREDITATION
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Dannemiller Memorial Educational Foundation and MedPro Communications, Inc. The Dannemiller Memorial Educational Foundation is accredited by the ACCME to provide continuing medical education for physicians.
DESIGNATION OF CME/CE CREDIT
The Dannemiller Memorial Educational Foundation designates this educational activity for a maximum of 1.0 category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in that activity.
This program has been approved for 1.2 contact hours of continuing education by the American Academy of Nurse Practitioners. Program ID 0503120
AANP Release Date: March 2005
AANP Expiration Date for Credit: October 31, 2006
STATEMENT OF NEED
Adverse premenstrual symptoms have deleterious effects on the quality of life of many reproductive-age women. These somatic and mood symptoms range in increasing severity and decreasing frequency from mildly bothersome premenstrual molimina, to the
well-characterized premenstrual syndrome, to the most severe and least frequent premenstrual dysphoric disorder (PMDD). The latter disorder is a defined psychiatric condition that consists of symptoms that markedly interfere with a woman's life. In the past, research in the area of premenstrual symptoms has been limited by a lack of defined criteria; however, the diagnostic criteria established by the American Psychiatric Association for PMDD have been used to identify subjects enrolled in increasing numbers of studies. Because the cyclic nature of premenstrual symptoms suggests a strong etiologic role for sex hormones, oral contraceptives (OCs) are often used to treat these disorders without data establishing efficacy. Although FDA-approved treatment options for PMDD are currently limited to selective serotonin reuptake inhibitors, other therapies are being studied, including OC formulations containing the novel progestin
drospirenone and the use of extended or continuous OC regimens to minimize cyclic symptoms. Clinicians should be informed of the recent investigations concerning treatment options for premenstrual disorders so that they can provide the most effective
counseling for their patients with bothersome premenstrual symptoms.
INTENDED AUDIENCE
This program has been developed for gynecologists and other physicians caring for reproductive-age women, plus other health professionals counseling patients on the treatment of premenstrual symptoms.
LEARNING OBJECTIVES
Upon completion of this activity, the participants will be able to:
- Differentiate between premenstrual syndrome and premenstrual dysphoric disorder (PMDD), and list the diagnostic criteria for PMDD.
- Discuss the impact of premenstrual symptoms and PMDD on a woman's quality of life, including the deleterious psychological, social, and economic effects associated with functioning at a suboptimal level during several days each cycle.
- Describe the role of hormones in the etiology of premenstrual symptoms.
- Discuss the FDA-approved and off-label therapies used to treat premenstrual symptoms; list some new agents and treatment regimens currently under study.
DISCLOSURES
The Dannemiller Memorial Educational Foundation requires that the faculty participating in a continuing medical education activity disclose to participants any significant financial interest or other relationship (1) with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity.
Dr. Daniel R. Mishell, Jr. discloses that he is a consultant/advisory board member for Berlex, Inc.
Dr. Patricia J. Sulak discloses that she participates in speaker programs for Berlex, Inc., Barr Laboratories, Wyeth and Ortho-McNeil Pharmaceuticals, Inc. She is also a
consultant/advisory board member for Berlex, Inc., Barr Laboratories and Wyeth. In addition, she is also an investigator for Berlex, Inc and Barr Laboratories.
Dr. Andrea J. Rapkin discloses that she participates in speaker programs for Tap Pharmaceuticals, Inc., Wyeth and Berlex, Inc.
To resolve any identified conflicts of interest of the faculty, the proposed educational content was fully reviewed. The resulting certified monograph was found to provide educational content that is current, evidence based and commercially balanced.
The Dannemiller Staff and MedPro Communications Staff that were involved in the development of this activity have no financial relationships with any commercial interest that are relevant to this activity.
METHOD OF PARTICIPATION
This activity should take approximately 1 hour to complete. The participant should, in order, read the objectives, read the monograph, and take the link to the registration for credit and posttest evaluation form. The evaluation form provides each participant the opportunity to comment on the extent to which educational objectives were met, the
quality of the instructional process, the perception of enhanced professional effectiveness, the perception of commercial bias and his or her views on future educational needs. To receive credit for this activity, follow the instructions provided on the post-test. The
continuing medical education credit is valid through October 31, 2007 and the AANP continuing education credit is valid through October 31, 2006. No credit will be given after this date.
OFF LABEL DISCUSSION
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. Further participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program. The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the Dannemiller Memorial Educational
Foundation, Berlex, Inc., or MedPro Communications, Inc. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon information contained within this educational activity.
In the event you are unable to print the certificate, please submit the post-test and then email editor@dannemiller.com and a certificate will be mailed to you within two weeks.
|
